High-dose intensity cyclophosphamide, epidoxorubicin, vincristine and prednisone by shortened intervals and granulocyte colony-stimulating factor in non-Hodgkin's lymphoma: a phase II study

P Pronzato, R Lionetto, F Botto, F Pensa, A Tognoni, P Pronzato, R Lionetto, F Botto, F Pensa, A Tognoni

Abstract

Twenty patients with non-Hodgkin's lymphoma were treated with a combination of cyclophosphamide (750 mg m(-2), day 1), epidoxorubicin (60 mg m(-2), day 1), vincristine (1.4 mg m(-2), day 1) and prednisone (100 mg m(-2), days 1-5) every 14 days. Shortening of intervals was associated with the prophylactic employment of granulocyte colony-stimulating factor (G-CSF; specifically, filgrastim) administered at a dose of 300 microg subcutaneously from day 6 to day 11. The ratio between actually delivered dose intensity and planned dose intensity was 1.0 in 18 out the 20 patients. Toxicity was acceptable; response rate and survival are in the expected range. The present study demonstrated the feasibility of acceleration of chemotherapy cycles to obtain dose intensification in non-Hodgkin's lymphoma.

References

    1. Cancer. 1981 Jan 1;47(1):207-14
    1. Anticancer Res. 1997 May-Jun;17(3C):2325-7
    1. J Clin Oncol. 1984 Nov;2(11):1281-8
    1. Ann Intern Med. 1985 May;102(5):596-602
    1. Control Clin Trials. 1989 Mar;10(1):1-10
    1. Am J Clin Oncol. 1989 Dec;12(6):481-5
    1. J Clin Oncol. 1990 Jun;8(6):963-77
    1. Acta Oncol. 1990;29(3):257-85
    1. J Clin Oncol. 1991 Jan;9(1):25-38
    1. J Clin Oncol. 1991 Feb;9(2):339-47
    1. Blood. 1992 Sep 15;80(6):1430-6
    1. N Engl J Med. 1993 Apr 8;328(14):1002-6
    1. Eur J Cancer. 1993;29A(5):687-92
    1. N Engl J Med. 1993 Sep 30;329(14):987-94
    1. Ann Oncol. 1993 Sep;4(8):651-6
    1. Br J Cancer. 1994 Mar;69(3):537-40
    1. J Clin Oncol. 1994 Apr;12(4):769-78
    1. Ann Oncol. 1995 Mar;6(3):211-7
    1. J Clin Oncol. 1995 Dec;13(12):2916-23
    1. Leukemia. 1996 Jan;10(1):175-7
    1. J Clin Oncol. 1996 Feb;14(2):351-6
    1. J Clin Oncol. 1996 Apr;14(4):1275-81
    1. Br J Cancer. 1996 Jun;73(11):1425-7
    1. J Clin Oncol. 1997 Apr;15(4):1367-76
    1. Ann Intern Med. 1983 Mar;98(3):304-9

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner